Nature Communications (Dec 2021)
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
- Michael Maschan,
- Paolo F. Caimi,
- Jane Reese-Koc,
- Gabriela Pacheco Sanchez,
- Ashish A. Sharma,
- Olga Molostova,
- Larisa Shelikhova,
- Dmitriy Pershin,
- Alexey Stepanov,
- Yakov Muzalevskii,
- Vinicius G. Suzart,
- Folashade Otegbeye,
- David Wald,
- Ying Xiong,
- Darong Wu,
- Adam Knight,
- Ibe Oparaocha,
- Beatrix Ferencz,
- Andre Roy,
- Andrew Worden,
- Winfried Kruger,
- Michael Kadan,
- Dina Schneider,
- Rimas Orentas,
- Rafick-Pierre Sekaly,
- Marcos de Lima,
- Boro Dropulić
Affiliations
- Michael Maschan
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Paolo F. Caimi
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- Jane Reese-Koc
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- Gabriela Pacheco Sanchez
- Emory University
- Ashish A. Sharma
- Emory University
- Olga Molostova
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Larisa Shelikhova
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Dmitriy Pershin
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Alexey Stepanov
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Yakov Muzalevskii
- Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
- Vinicius G. Suzart
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- Folashade Otegbeye
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- David Wald
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- Ying Xiong
- Lentigen, A Miltenyi Biotec Company
- Darong Wu
- Lentigen, A Miltenyi Biotec Company
- Adam Knight
- Lentigen, A Miltenyi Biotec Company
- Ibe Oparaocha
- Lentigen, A Miltenyi Biotec Company
- Beatrix Ferencz
- Lentigen, A Miltenyi Biotec Company
- Andre Roy
- Lentigen, A Miltenyi Biotec Company
- Andrew Worden
- Lentigen, A Miltenyi Biotec Company
- Winfried Kruger
- Lentigen, A Miltenyi Biotec Company
- Michael Kadan
- Lentigen, A Miltenyi Biotec Company
- Dina Schneider
- Lentigen, A Miltenyi Biotec Company
- Rimas Orentas
- Lentigen, A Miltenyi Biotec Company
- Rafick-Pierre Sekaly
- Emory University
- Marcos de Lima
- University Hospitals Seidman Cancer Center, Case Western Reserve University
- Boro Dropulić
- Lentigen, A Miltenyi Biotec Company
- DOI
- https://doi.org/10.1038/s41467-021-27312-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Strategies to address the challenges associated with product manufacturing can improve chimeric antigen receptor (CAR) cell–based therapeutics. Here the authors report the results of two clinical trials in patients with B-cell malignancies, showing that place-of-care manufacturing has a low production failure rate with CD19-directed CAR-T cell products inducing high remission rates.
